| Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study RF Grace, P Bianchi, EJ van Beers, SW Eber, B Glader, HM Yaish, ... Blood, The Journal of the American Society of Hematology 131 (20), 2183-2192, 2018 | 157 | 2018 |
| Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis O Niss, S Chonat, N Dagaonkar, MO Almansoori, K Kerr, ZR Rogers, ... Blood Cells, Molecules, and Diseases 61, 4-9, 2016 | 75 | 2016 |
| Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease S Chonat, MO Quarmyne, CM Bennett, CL Dean, CH Joiner, RM Fasano, ... Haematologica 103 (10), e483, 2018 | 62 | 2018 |
| Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion MA Carden, ME Fay, X Lu, RG Mannino, Y Sakurai, JC Ciciliano, ... Blood, The Journal of the American Society of Hematology 130 (24), 2654-2663, 2017 | 60 | 2017 |
| Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency P Bianchi, E Fermo, K Lezon‐Geyda, EJ van Beers, HD Morton, ... American journal of hematology 95 (5), 472-482, 2020 | 54 | 2020 |
| Mitapivat versus placebo for pyruvate kinase deficiency H Al-Samkari, F Galactéros, A Glenthøj, JA Rothman, O Andres, RF Grace, ... New England Journal of Medicine 386 (15), 1432-1442, 2022 | 53 | 2022 |
| Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal SL Thein, F Pirenne, RM Fasano, A Habibi, P Bartolucci, S Chonat, ... Haematologica 105 (3), 539, 2020 | 53 | 2020 |
| Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study EJ Van Beers, S Van Straaten, DH Morton, W Barcellini, SW Eber, ... Haematologica 104 (2), e51, 2019 | 53 | 2019 |
| Current standards of care and long term outcomes for thalassemia and sickle cell disease S Chonat, CT Quinn Gene and cell therapies for beta-globinopathies, 59-87, 2017 | 52 | 2017 |
| Use of premedication for intubation in tertiary neonatal units in the United Kingdom R Chaudhary, S Chonat, H Gowda, P Clarke, A Curley Pediatric Anesthesia 19 (7), 653-658, 2009 | 48 | 2009 |
| The Spectrum of SPTA1-Associated Hereditary Spherocytosis S Chonat, M Risinger, H Sakthivel, O Niss, JA Rothman, L Hsieh, ... Frontiers in physiology 10, 815, 2019 | 43 | 2019 |
| Complement serves as a switch between CD4+ T cell–independent and–dependent RBC antibody responses A Mener, SR Patel, CM Arthur, S Chonat, A Wieland, M Santhanakrishnan, ... JCI insight 3 (22), 2018 | 41 | 2018 |
| Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice PE Zerra, SR Patel, RP Jajosky, CM Arthur, JW McCoy, JWL Allen, ... Blood, The Journal of the American Society of Hematology 138 (8), 706-721, 2021 | 40 | 2021 |
| Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice SR Patel, A Bennett, K Girard-Pierce, CL Maier, S Chonat, CM Arthur, ... Blood Advances 2 (2), 105-115, 2018 | 35 | 2018 |
| Marginal zone B cells induce alloantibody formation following RBC transfusion SR Patel, DR Gibb, K Girard-Pierce, X Zhou, LC Rodrigues, CM Arthur, ... Frontiers in Immunology 9, 2516, 2018 | 33 | 2018 |
| Examining the role of complement in predicting, preventing, and treating hemolytic transfusion reactions CM Arthur, S Chonat, R Fasano, MEM Yee, CD Josephson, JD Roback, ... Transfusion medicine reviews 33 (4), 217-224, 2019 | 31 | 2019 |
| Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia A Hecht, JA Meyer, A Behnert, E Wong, F Chehab, A Olshen, A Hechmer, ... Haematologica 107 (1), 178, 2022 | 29 | 2022 |
| Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease S Chonat, S Graciaa, HS Shin, JG Newton, MO Quarmyne, J Boudreaux, ... Haematologica 105 (12), 2887, 2020 | 27 | 2020 |
| Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial A Glenthøj, EJ van Beers, H Al-Samkari, V Viprakasit, KHM Kuo, ... The Lancet Haematology 9 (10), e724-e732, 2022 | 25 | 2022 |
| Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion S Chonat, CM Arthur, PE Zerra, CL Maier, RP Jajosky, MEM Yee, ... Transfusion Clinique et Biologique 26 (2), 130-134, 2019 | 24 | 2019 |
Patricia E. ZerraAssistant Professor, Emory UniversityVerified email at emory.edu
